SCHEMBL8407943

SCHEMBL8407943

CCCCOC(=O)CC(N)C(=O)OCCCC

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.47
ALDH1A1 P00352 1/20 0.47
NPSR1 Q6W5P4 2/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ATM Q13315 1/20 0.44
DGKA P23743 1/20 0.42
HTR2C P28335 1/20 0.42
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
RAD52 P43351 1/20 0.41
P2RY10 O00398 4/20 0.40
GPR34 Q9UPC5 2/20 0.40
FAAH O00519 1/20 0.40
HCAR2 Q8TDS4 1/20 0.39
NOD1 Q9Y239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1396441 1.00 NAAA (0.47) NAAAALDH1A1NPSR1MAPTMAPK1
SCHEMBL14514324 1.00 NAAA (0.47) NAAAALDH1A1NPSR1MAPTMAPK1
Hydrochloric Acid SCHEMBL3914765 0.98 NPSR1 (0.48) NAAAALDH1A1NPSR1MAPTMAPK1
Hydrochloric Acid SCHEMBL3914767 0.98 NPSR1 (0.48) NAAAALDH1A1NPSR1MAPTMAPK1
SCHEMBL1644712 0.94 NAAA (0.55) NAAANPSR1MAPTMAPK1L3MBTL1
SCHEMBL472925 0.94 NAAA (0.55) NAAANPSR1MAPTMAPK1L3MBTL1
SCHEMBL17231345 0.93 NAAA (0.58) NAAANPSR1MAPTMAPK1L3MBTL1
SCHEMBL9442151 0.93 NAAA (0.58) NAAANPSR1MAPTMAPK1L3MBTL1
SCHEMBL2283336 0.93 NAAA (0.58) NAAANPSR1MAPTMAPK1L3MBTL1
SCHEMBL2279558 0.93 NAAA (0.58) NAAANPSR1MAPTMAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122037683-A Waterproof coating modifying treatment method 上海理工大学 2026-05-15 CN claimed
CN-122037683-A Waterproof coating modifying treatment method 上海理工大学 2026-05-15 CN disclosed
CN-118240279-A Plasticizer, plastic composition and plastic product 星欧光学股份有限公司 2024-06-25 CN disclosed
US-20220015393-A1 APPLICATION OF ASPARTIC ACID DERIVATIVE IN PREPARING ANIMAL FEED ADDITIVE Anipha Technologies Pty Ltd (AU) 2022-01-20 US disclosed
EP-3512486-B1 BLUE POWDER AND USE THEREOF IN COSMETICS OREAL (FR) 2020-10-21 EP disclosed
EP-3512486-A1 BLUE POWDER AND USE THEREOF IN COSMETICS L'Oreal (FR) 2019-07-24 EP disclosed
CN-109689010-A Blue powder and its purposes in cosmetics 莱雅公司 2019-04-26 CN disclosed
WO-2018050504-A1 BLUE POWDER AND USE THEREOF IN COSMETICS L'OREAL (FR) 2018-03-22 WO disclosed
US-9439986-B2 Tricarbonyl technetium-99m, rhenium-185/187, or rhenium-188 labeled cyclic RGD derivatives and uses thereof BIO IMAGING KOREA CO., LTD. (KR) 2016-09-13 US disclosed
EP-2583966-B1 TRICARBONYL TECHNETIUM-99M OR RHENIUM-188 LABEL RING RGD DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE AS AN ACTIVE INGREDIENT FOR USE IN THE DIAGNOSIS OR TREATMENT OF ANGIOGENESIS-RELATED DISEASES BIO IMAGING KOREA CO LTD (KR) 2016-08-10 EP disclosed
US-20070135385-A1 Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction ILYPSA, INC. 2007-06-14 US disclosed
US-20070135383-A1 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors ILYPSA, INC. 2007-06-14 US disclosed
WO-2007056279-A2 PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS ILYPSA, INC. (US) 2007-05-18 WO disclosed
WO-2007056281-A2 MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS ILYPSA, INC. (US) 2007-05-18 WO disclosed
WO-2007056184-A2 AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS ILYPSA, INC. (US) 2007-05-18 WO disclosed
EP-0927264-A1 REGIOSELECTIVE alpha-HYDROLYSIS OF AMINO ACID DIESTERS USING PIG LIVER ESTERASE NSC Technologies LLC (US) 1999-07-07 EP disclosed
WO-1998008968-A1 REGIOSELECTIVE α-HYDROLYSIS OF AMINO ACID DIESTERS USING PIG LIVER ESTERASE NSC TECHNOLOGIES LLC (US) 1998-03-05 WO disclosed
EP-0299362-B1 PROCESS FOR PREPARING PYRIDINE-2,3- DICARBOXYLIC ACID COMPOUNDS Daiso Co., Ltd. (JP) 1991-12-04 EP disclosed
US-4948896-A REACTING AN ENONE AND AN AMINODIESTER DAISO CO., LTD. (JP) 1990-08-14 US disclosed
EP-0299362-A1 Process for preparing pyridine-2,3- dicarboxylic acid compounds Daiso Co., Ltd. (JP) 1989-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135385-A1 Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction GPR119, INMT, PNLIP NAAA 1049/4885ALDH1A1 2180/4885NPSR1 2004/4885
US-20070135383-A1 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors PNLIP, PLA2G2E, PLA2G3 NAAA 159/4885ALDH1A1 3723/4885NPSR1 1734/4885
US-20220015393-A1 APPLICATION OF ASPARTIC ACID DERIVATIVE IN PREPARING ANIMAL FEED ADDITIVE AADAT, SLC1A5, SLC1A3 NAAA 83/4885ALDH1A1 1813/4885NPSR1 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.